24-Week Recurrence Rate of Gout Following Firsekibart Treatment

Inclusion Criteria: 1. Age 18 to 75 years (inclusive), male or female; 2. Meet the 2015 ACR/EULAR Gout Classification Criteria; 3. Two or more acute gout flares within a year; 4. In the acute phase of a gout flare; 5. Voluntarily signed the Informed Consent Form (ICF). Exclusion Criteria: 1. History of hypersensitivity to the study drug or similar classes of drugs; 2. Pregnant or breastfeeding women; 3. History of clinically significant diseases, including: Chronic congestive heart failure (NYHA Class IV); History of echocardiography-confirmed ejection fraction (EF) \< 30%; Myocardial infarction, acute coronary syndrome, viral myocarditis, or pulmonary embolism within 6 months; Coronary revascularization within 6 months; Severe arrhythmia requiring treatment with Class Ia or III antiarrhythmic drugs;History of sick sinus syndrome, Mobitz II and Complete Heart Block without a permanent pacemaker implanted; QTc interval≥480 ms on screening ECG ; 4. Confirmed active tuberculosis infection; 5. History of severe immunodeficiency, including positive human immunodeficiency virus (HIV) antibody, or other acquired or congenital immunodeficiency diseases; 6. Presence of infection requiring systemic treatment within 7 days prior to screening; 7. Laboratory abnormalities at screening as follows: White blood cellcount or absolute neutrophil count below the lower limit of normal at the study site; Platelet count ≤100×10\^9/L; Total bilirubin \> 1.5 times ULN (Upper Limit of Normal); AST/ALT \> 3 times ULN; Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73m²; Triglycerides \> 5.7 mmol/L; 8. Any other conditions that, in the opinion of the investigator, may affect the evaluation of efficacy or safety in this study.